Pfizer Chantix Trials Show More Heart Troubles In Users: FDA

Law360, New York (December 12, 2012, 8:32 PM EST) -- An analysis of clinical trials has shown that users of Pfizer Inc.'s smoking cessation drug Chantix had a higher occurrence of heart attacks, strokes and other cardiovascular adverse events compared to patients who took a placebo, the U.S. Food and Drug Administration said Wednesday.

The events were uncommon among both the Chantix and placebo users and the increased risk wasn't statistically significant, the FDA said, meaning it's uncertain whether the excess risk for Chantix users was due to the drug or chance.

"However, the data were...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.